Nanotechnology for Cancer Therapy Based on Chemotherapy

Zhao, Chenyang; Cheng, Rui; Yang, Zhe; Tian, Zhongmin

doi:10.3390/molecules23040826

Cited by 262 publications

(139 citation statements)

References 241 publications

(267 reference statements)

Supporting

Mentioning

138

Contrasting

Unclassified

Order By: Relevance

“…For example, the results of the present study indicated that IQGAP1 is a potential target for CRC treatment and further highlighted that miR-124 is in theory a potential way to antagonize IQGAP1 similar to the WW domain peptide of IQGAP1 mentioned. Recently, nanoparticles have emerged as a popular concept for targeted delivery of therapeutic agents to tumors (37)(38)(39). A type of combined polymeric nanoparticle (PNP) entrapping phosphatidyl inositol 3 kinase inhibitors or irinotecan suppresses or even eliminates lung metastasis of CRC in a BALB/C mice model, but negligible accumulation of PNPs is detected in the organs including the spleen, liver and kidneys indicating good tissue selectivity of PNPs and organ safety (40).…”

Section: Discussionmentioning

confidence: 99%

miR‑124 inhibits cell growth through targeting IQGAP1 in colorectal cancer

Fan

Zhang

et al. 2018

Mol Med Report

View full text Add to dashboard Cite

MicroRNA (miRNA/miR)-124 is a miRNA, which exerts tumor suppressive effects but is frequently absent in tumors. Although it has been validated to target oncogenic genes such as signal transducer and activator of transcription 3, forkhead box Q1, and Slug, the mechanistic link between miR-124 and potential target genes that contribute to tumor progression, is yet to be investigated. IQ motif containing GTPase activating protein 1 (IQGAP1) is a scaffold protein that participates in protein-protein interactions and integrating diverse signaling pathways. Previous studies suggest that overexpression of IQGAP1 enhances activity of mitogen activated protein kinase 1 and β-catenin signaling cascades to facilitate tumor progression. The present study aimed to identify the regulative link between miR-124 and IQGAP1 in colorectal cancer (CRC). It was demonstrated that IQGAP1 was aberrantly overexpressed in CRC tissues and cell lines. Knockdown of IQGPA1 by introducing short hairpin-IQGAP1 lentivirus inhibited CRC cell growth and colony formation ability, and simultaneously suppressed phosphorylation of extracellular signal-regulated kinase (ERK)1/2 and β-catenin expression. Furthermore, it was demonstrated that miR-124 was silenced in CRC. Restoration of miR-124 in CRC cells impeded cell growth and colony formation ability. The direct binding of miR-124 to the 3'untranslated region of IQGAP1 mRNA was confirmed using a luciferase reporter gene assay. Importantly, downregulation of IQGAP1 expression was observed in miR-124-restoration cells with simultaneous reduction of phosphorylated-ERK1/2 and β-catenin. In conclusion, the present study describes a potential mechanism underlying the miR-124/IQGAP1 link in CRC progression. Silencing of miR-124 may depress IQGAP1 expression, leading to increased activity of ERK1/2 and β-catenin signaling.

show abstract

Section: Discussionmentioning

confidence: 99%

miR‑124 inhibits cell growth through targeting IQGAP1 in colorectal cancer

Fan

Zhang

et al. 2018

Mol Med Report

View full text Add to dashboard Cite

show abstract

“…During the past years, nanotechnology-based diagnostic and therapeutic systems have provided potential solutions for cancer treatments. [10][11][12][13] Multifunctional nanosystems (NSs) in conjugation with various imaging probes and targeting agents such as antibodies (Abs)/aptamers (Aps), and enzymes have been recently developed for cancer therapy. [14][15][16] Among different types of NSs, the greater affinity, specificity, and functionality of enzymes to selectively target the desired cells/tissues make them prominent treatment modalities for a variety of diseases.…”

Section: Synthesis Of Peg Ligands Sh-peg-coohmentioning

confidence: 99%

PEGylated gold nanoparticles-ribonuclease induced oxidative stress and apoptosis in colorectal cancer cells

et al. 2019

View full text Add to dashboard Cite

Introduction: Currently, drug-induced reactive oxygen species (ROS) mediating apoptosis pathway have extensively been investigated in designing effective strategies for colorectal cancer (CRC) chemotherapy. Bovine pancreatic ribonuclease A (RNase A) represents a new class of cytotoxic and non-mutagenic enzymes, and has gained more attention as a potential anticancer modality; however, the cytosolic ribonuclease inhibitors (RIs) restrict the clinical application of this enzyme. Nowadays, nanotechnology-based diagnostic and therapeutic systems have provided potential solutions for cancer treatments. Methods: In this study, the gold nanoparticles (AuNPs) were synthesized, stabilized by polyethylene glycol (PEG), functionalized, and covalently conjugated with RNase A. The physicochemical properties of engineered nanobiomedicine (AuNPs-PEG-RNase A) were characterized by scanning electron microscope (SEM), dynamic light scattering (DLS), and UV-vis spectrum. Then, its biological impacts including cell viability, apoptosis, and ROS production were evaluated in the SW-480 cells. Results: The engineered nanobiomedicine, AuNPs-PEG-RNase A, was found to effectively induce apoptosis in SW-480 cells and result in a significant reduction in cancer cell viability. Besides, the maximum production of ROS was obtained after the treatment of cells with an IC50 dose of AuNPs-PEG-RNase A. Conclusion: Based on the efficient ROS-responsiveness and the anticancer activity of RNase A of the engineered nanomedicine, this nanoscaled biologics may be considered as a potential candidate for the treatment of CRC.

show abstract

“…Nanotechnology often overcomes the chemotherapy associated issues [8]. Nanotechnologybased carriers primarily aimed to improve the therapeutic efficacy of anticancer agents by increasing bioavailability, solubility, and retention time at the tumor sites.…”

Section: Introductionmentioning

confidence: 99%

Pectin-Tannic Acid Nano-Complexes Promote the Delivery and Bioactivity of Drugs in Pancreatic Cancer Cells

et al. 2020

View full text Add to dashboard Cite

Pancreatic cancer (PanCa) is a lethal disease. Conventional chemotherapies for PanCa offer severe systemic toxicities. Thus, the development of a successful nanomedicine-based therapeutic regimen with augmented therapeutic efficacy is highly sought. Naturally occurring pectin and modified pectin-based drug delivery systems exhibit remarkable self-targeting ability via galactose residues to various cancer cells. Herein, we developed and used an innovative approach of highly stable nanocomplexes based on modified pectin and tannic acid (MPT-NCs). The nanocomplex formation was enabled by strong intermolecular interactions between pectin and tannic acid under very mild conditions. These nanocomplexes were characterized by particle size and morphology (DLS, TEM, and SEM), FT-IR spectroscopy, and zeta potential measurements. Additionally, MPT-NCs were capable of encapsulating anticancer drugs (5-fluorouracil, gemcitabine, and irinotecan) through tannic acid binding. The in vitro bioactivity of these drug MPT-NCs were evaluated in pancreatic cancer adenocarcinoma (PDAC) cell lines (HPAF-II and PANC-1). A dose-dependent internalization of nanocomplexes was evident from microscopy and flow cytometry analysis. Both proliferation and colony formation assays indicated the anticancer potential of pectin drug nanocomplexes against PDAC cells compared to that of free drug treatments. Together, the pectin-based nanocomplexes could be a reliable and efficient drug delivery strategy for cancer therapy.

show abstract

Nanotechnology for Cancer Therapy Based on Chemotherapy

Cited by 262 publications

References 241 publications

miR‑124 inhibits cell growth through targeting IQGAP1 in colorectal cancer

miR‑124 inhibits cell growth through targeting IQGAP1 in colorectal cancer

PEGylated gold nanoparticles-ribonuclease induced oxidative stress and apoptosis in colorectal cancer cells

Pectin-Tannic Acid Nano-Complexes Promote the Delivery and Bioactivity of Drugs in Pancreatic Cancer Cells

Contact Info

Product

Resources

About